<DOC>
	<DOCNO>NCT01157052</DOCNO>
	<brief_summary>The investigator hypothesize Ca2+/MG2+ infusion significant effect oxaliplatin pharmacokinetics .</brief_summary>
	<brief_title>Oxaliplatin Pharmacokinetics With Without Ca2+/MG2+ Infusion Colorectal Cancer Patients</brief_title>
	<detailed_description>This clinical pharmacology prospective non-randomized trial determine oxaliplatin pharmacokinetics presence absence calcium magnesium supplementation .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients must Metastatic Colorectal Cancer ( stage IV ) Patients treat 5FU leucovorin adjuvant set 5FU leucovorin ( LV ) or/and FOLFIRI regimen metastatic setting may eligible trial . Patients must ≥ 18 year Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Patients must adequate renal function creatinine &lt; 1.5mg/dl creatinine clearance &gt; 45ml/min . Patients must adequate hepatic function bilirubin &gt; 1.5 mg/dl AST ( normal range 014/L ) ALT ( normal range 049 U/L ) absence liver metastasis &lt; /= 5X upper limit normal AST ALT presence liver metastasis . Patients must adequate bone marrow function absolute neutrophil count ( ANC ) ≥ 1,500/цl platelet ≥ 100,000/цl hemoglobin ≥ 10g/d . Patients must willing able comply study protocol study duration patient must give write informed consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Also , woman childbearing potential men must agree use adequate contraception prior study entry duration study participation . The investigator request advise patient achieve adequate contraception . Life expectancy longer 6 month Patients receive oxaliplatin previously Patients known peripheral neuropathy ≥ grade 2 accord WHO scale Patients test positive HIV Patients significant medical , psychiatric disorder tha , opinion investigator , exclude patient study compliance safety reason . Patients swallow History know allergy oxaliplatin platinum compound , 5FU , LV , ingredient formulation container Participation another clinical trial investigational drug within 30 day prior study screen Pernicious anemia megaloblastic anemia vitamin B12 deficiency Patient concomitant treatment drugs/ingredients report potential activity prevent peripheral sensory neuropathy ( PSN ) Patients n't successfully complete local therapy previously treat CNS metastasis &amp; n't discontinue corticosteroid &gt; 4kws start chemotherapy . Patients asymptomatic brain mets evidence midline shift CT/MRI may enrol without initiation local therapy CNS mets . Repeat scan must perform &lt; 4wks ensure progression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>magnesium</keyword>
	<keyword>calcium</keyword>
	<keyword>adverse effect</keyword>
	<keyword>kinetics , drug</keyword>
</DOC>